Sunday 18 October 2026
Export IMMP’s income statement to Excel — free account
Prima BioMed Ltd
IMMP Healthcare Biotechnology
Prima BioMed Ltd’s revenue for fiscal 2026 (year ended June 2026) was $16.4 million, up 145.2% from fiscal 2025. Revenue growth for three consecutive years.
3.20
0.01
−0.31%
Follow IMMP
| Jun '26 | Jun '25 | Jun '24 | Jun '23 | Jun '22 | Jun '21 | Jun '20 | Jun '19 | Jun '18 | Jun '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 2 | 5 | 3 | 5 | 3 | 4 | 1 | 3 | 4 |
P/E ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(10.45) | (3.28) | (1.32) | (2.30) | (3.23) | (3.45) | (7.94) | (9.59) | (7.14) | (9.38) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(18.43) | 5.22 | 14.78 | 9.29 | 5.88 | 1.31 | (14.52) | (19.43) | (12.56) | (17.62) |
P/Operating CF |
(0.02) | (0.09) | (1.21) | (1.27) | (1.23) | (2.34) | (0.65) | (1.04) | (1.49) | (1.30) |
Beneish M-Score |
(3.49) | (2.28) | (2.64) | (2.83) | (2.18) | 1.83 | (2.38) | (2.53) | (2.45) | 3.30 |
P/B ratio |
0.01 | 0.02 | 0.03 | 0.04 | 0.03 | 0.09 | 0.06 | 0.08 | 0.12 | 0.10 |
Price to Tangible BV |
0.01 | 0.02 | 0.03 | 0.05 | 0.03 | 0.12 | 0.13 | 0.23 | 0.33 | 0.29 |
EV/Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
1.42 | 3.07 | 1.71 | 1.40 | 3.17 | 2.05 | 0.45 | 0.18 | 0.14 | 0.15 |
EV/FCF |
1.42 | 3.06 | 1.71 | 1.40 | 3.17 | 2.04 | 0.45 | 0.18 | 0.14 | 0.15 |
Quick Ratio |
5.53 | 10.94 | 18.04 | 13.44 | 13.78 | 12.49 | 8.80 | 4.11 | 6.98 | 5.48 |
Current Ratio |
5.69 | 11.69 | 18.25 | 13.81 | 14.16 | 12.81 | 9.26 | 4.44 | 7.43 | 6.05 |
Net Debt/EBITDA |
0.92 | 2.24 | 4.49 | 3.25 | 2.63 | 2.97 | 1.71 | 0.58 | 1.70 | 0.84 |
Debt/Assets |
0.00% | 0.70% | 0.48% | 0.57% | 1.42% | 3.08% | 18.86% | 18.85% | 14.14% | 16.53% |
Debt/Equity |
0.00 | 0.01 | 0.01 | 0.01 | 0.02 | 0.03 | 0.26 | 0.31 | 0.20 | 0.22 |
Asset Turnover |
0.21 | 0.06 | 0.04 | 0.04 | 0.07 | 0.06 | 0.37 | 0.16 | 0.18 | 0.11 |
Operating CF/Net income |
0.70 | 1.01 | 0.82 | 0.89 | 0.94 | 0.59 | 0.80 | 0.83 | 0.61 | 0.91 |
Capex/Depreciation |
(0.04) | (0.11) | (0.41) | (0.04) | (0.01) | 0.00 | (0.01) | (0.02) | (0.01) | 0.00 |
| (79.87%) | (36.62%) | (25.92%) | (33.55%) | (38.00%) | (57.95%) | (45.44%) | (60.41%) | (42.97%) | (30.88%) | |
| (68.06%) | (34.02%) | (24.21%) | (30.98%) | (34.51%) | (48.27%) | (30.00%) | (40.10%) | (31.47%) | (24.62%) | |
ROIC |
0.00% | (248.37%) | (309.31%) | (178.93%) | (128.28%) | (80.32%) | (48.85%) | (70.12%) | (43.76%) | (29.12%) |
Return on Tangible Assets |
(119.12%) | (45.04%) | (23.61%) | (31.85%) | (38.15%) | (47.37%) | (48.38%) | (100.26%) | (51.36%) | (70.37%) |
Average Days of Receivables |
142.11 | 348.64 | 342.26 | 558.16 | 452.26 | 563.32 | 72.86 | 253.14 | 170.35 | 189.70 |
Research and Development Expense of Revenue |
380.43% | 594.41% | 530.02% | 697.24% | 463.76% | 434.38% | 123.61% | 221.53% | 135.86% | 178.27% |
Selling, General and Administrative Expense of Revenue |
39.63% | 83.67% | 112.93% | 166.92% | 106.69% | 158.31% | 38.40% | 85.00% | 98.49% | 102.97% |
Intangible Assets out of Total Assets |
0.02 | 0.05 | 0.04 | 0.06 | 0.10 | 0.16 | 0.33 | 0.42 | 0.39 | 0.54 |
Share Based Compensation of Revenue |
6.58% | 11.26% | 22.92% | 38.49% | 22.00% | 0.00% | 10.45% | 21.12% | 30.79% | 20.42% |
Graham Net Nets |
137.85 | 62.76 | 32.77 | 19.80 | 33.32 | 8.47 | 7.29 | 4.31 | 3.00 | 3.43 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | — | — | (125.00%) | (183.91%) | (180.30%) | (234.88%) |
Free Cash Flow Yield |
(9,715.82%) | (1,863.52%) | (1,684.41%) | (1,218.02%) | (973.19%) | (373.23%) | (1,476.27%) | (1,013.20%) | (705.55%) | (806.81%) |
Revenue per Share |
2.23 | 0.92 | 0.86 | 0.78 | 1.16 | 1.00 | 5.53 | 3.32 | 4.37 | 3.07 |
Operating CF per Share |
(5.12) | (5.52) | (3.80) | (5.33) | (5.17) | (4.43) | (3.63) | (6.78) | (4.62) | (6.19) |
Capex per Share |
(0.01) | (0.02) | (0.10) | (0.01) | 0.00 | 0.00 | (0.01) | (0.02) | (0.01) | 0.00 |
Free Cash Flow per Share |
(5.12) | (5.54) | (3.90) | (5.35) | (5.17) | (4.44) | (3.64) | (6.80) | (4.63) | (6.19) |
Cash per Share |
6.35 | 11.54 | 19.86 | 18.62 | 13.67 | 15.22 | 8.82 | 7.35 | 13.96 | 8.90 |
Shareholders Equity per Share |
5.68 | 12.78 | 20.70 | 20.59 | 16.08 | 18.41 | 11.15 | 10.81 | 19.93 | 19.30 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.68 | 12.78 | 20.70 | 20.59 | 16.08 | 18.41 | 11.15 | 10.81 | 19.93 | 19.30 |
Free Cash Flow |
(37.71) | (40.36) | (23.45) | (23.86) | (21.95) | (13.19) | (7.29) | (10.96) | (6.04) | (6.42) |
Working Capital |
45.11 | 88.29 | 118.61 | 84.28 | 61.23 | 47.13 | 18.66 | 13.05 | 19.22 | 10.02 |
Capital Expenditures |
(0.06) | (0.18) | (0.61) | (0.06) | (0.02) | (0.01) | (0.01) | (0.03) | (0.01) | 0.00 |
Net Current Asset Value |
39.97 | 87.91 | 117.58 | 83.47 | 60.01 | 44.58 | 11.99 | 5.28 | 11.76 | 5.65 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.03 | 0.12 | 0.02 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
22.35 | 37.65 | 35.83 | 24.79 | 54.44 | 0.00 | 42.19 | 35.46 | 68.41 | 70.48 |
Cash ROIC |
(42.60%) | (22.71%) | (9.60%) | (13.59%) | (17.24%) | (12.95%) | (15.87%) | (31.54%) | (12.24%) | (19.11%) |
Accounts Receivable Turnover |
2.57 | 1.19 | 1.01 | 0.61 | 0.92 | 0.87 | 3.74 | 1.68 | 2.64 | 3.58 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
6.39 | 5.61 | 5.09 | 5.71 | 5.33 | 3.39 | 2.96 | 3.19 | 2.16 | 0.89 |
Average Payables |
7.99 | 6.58 | 6.17 | 5.12 | 3.87 | 2.77 | 2.79 | 3.23 | 2.40 | 1.49 |
Average Assets |
79.09 | 116.93 | 115.73 | 86.69 | 67.71 | 46.29 | 30.14 | 32.72 | 31.40 | 28.68 |
Average Common Equity |
67.39 | 108.65 | 108.08 | 80.06 | 61.50 | 38.55 | 19.90 | 21.72 | 23.00 | 22.87 |
Columns are period end dates · fundamentals updated 2 Oct 2026